Nutriband Inc. Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the development of abuse-deterrent opioid therapies with its proprietary AVERSA technology. The company is focusing on buprenorphine, an FDA-approved medication for treating opioid use disorder and chronic pain, through a transdermal delivery system. This innovation is projected to achieve peak annual sales between $70 million and $130 million, marking a potential turning point in the fight against the opioid crisis.

The urgency for safer opioid treatments is underscored by the ongoing public health crisis in the United States and globally. Nutriband's AVERSA technology offers a promising solution by deterring misuse of opioid-based therapies, setting a new standard in transdermal treatments. The AVERSA pipeline includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine, both designed to provide effective pain management while minimizing the risk of abuse.

Buprenorphine's role as a cornerstone in treating opioid use disorder highlights the importance of Nutriband's development. By leveraging AVERSA technology, the company aims to enhance the safety and efficacy of buprenorphine therapy, offering hope for millions affected by opioid addiction and chronic pain. This advancement not only represents a significant leap forward in medical technology but also addresses a critical need in public health, potentially reducing the societal and economic burdens of the opioid epidemic.